Announcement PDF NOTICE OF ANNUAL GENERAL MEETING Including Explanatory Notes and Proxy Form To be held: 10:00 am AEDT on Wednesday, 7 October 2026 Hamilton Locke, Level 10 161 Collins Street Melbourne Victoria 3000 -and- Virtually at this web address - https://meetings.lumiconnect.com/300-317-173-369 Meeting ID: 300-317-173-369 This is an important document. It should be read in its entirety. If you are in doubt as to the course you should follow, consult your financial or other professional adviser. This page has been left blank intentionally. Page 2 of 46 PERCHERON THERAPEUTICS LIMITED ACN 095 060 745 NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the Annual General Meeting of Percheron Therapeutics Limited ACN 095 060 745 (Company) will be held both in person and virtually at 10:00 am (AEDT) on Wednesday, 7 October 2026 for the purposes of considering and, if thought fit, passing each of the resolutions referred to in this Notice of Meeting. Physical address Hamilton Locke, Level 10 161 Collins Street Melbourne Vic 3000 Virtual address https://meetings.lumiconnect.com/300-317-173-369 Meeting ID: 300-317-173-369 The Explanatory Notes and proxy form accompanying this Notice of Meeting are hereby incorporated in, and comprise part of, this Notice of Meeting. Please read this Notice of Meeting carefully and consider directing your proxy on how to vote on each resolution by marking the appropriate box on the proxy form included with this Notice of Meeting. Shareholders who intend to appoint the Chair as proxy (including an appointment by default) should have regard to the important information below under the heading "Appointing the chair as your proxy". BUSINESS OF THE MEETING 2026 Annual Financial Report To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2026, comprising the Financial Report, the Directors’ Report, and the Auditor's Report (2026 Annual Report). At the Meeting, a representative of the Company’s auditor, William Buck will be available to answer any questions about the conduct of the audit, the preparation and content of the Auditor's Report, the accounting policies adopted by the Company in relation to the preparation of the financial statements and the independence of the auditor in relation to the conduct of the audit. Note: there is no requirement for Shareholders to approve the Annual Report. Resolution 1: Non-Binding Resolution to Adopt the 2026 Remuneration Report To consider, and if thought fit, pass with or without amendment the following resolution as an advisory and non- binding ordinary resolution: “That for the purposes of section 250R(2) of the Corporations Act, the Remuneration Report for the financial year ended 30 June 2026, as disclosed in the Directors’ Report is adopted.” The vote on this Resolution is advisory only and does not bind the Directors or the Company. A voting prohibition statement applies to this Resolution. Please see below. Resolution 2: Election of Director – Dr James Garner To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: “That, Dr James Garner, a Director of the Company, who retires in accordance with the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director of the Company.” Page 3 of 46 The Board (with Dr Garner abstaining) recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 2. Resolution 3: Approval for issue of Restricted Stock Units to Dr Michael Baker To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: “That for the purposes of Listing Rule 10.11 and for all other purposes, Shareholders approve the issue of up to 75,000,000 Restricted Stock Units to the Company’s CEO and Managing Director Dr Michael Baker or his nominee(s), on the terms and conditions set out in the Explanatory Notes." A voting prohibition statement and voting exclusion statement apply to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 3. Resolution 4: Ratification of Prior Issue of Adviser Options to Blue Ocean To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: "That, for the purposes of Listing Rule 7.4 and all other purposes, Shareholders ratify the prior issue of 27,500,000 Adviser Options to Blue Ocean or its nominee/s, on the terms and conditions and in the manner detailed in the Explanatory Notes." A voting exclusion statement applies to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 4. Resolution 5: Ratification of Prior Issue of Joint Lead Manager Options to Blue Ocean and Cygnet Capital To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: "That, for the purposes of Listing Rule 7.4 and all other purposes, Shareholders ratify the prior issue of 50,000,000 Joint Lead Manager Options to Blue Ocean and Cygnet Capital or their respective nominee/s, on the terms and conditions and in the manner detailed in the Explanatory Notes.” A voting exclusion statement applies to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 5. Resolution 6: Re-approval of Percheron Therapeutics Employee Share Option Plan To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: "That for the purposes of Listing Rules 7.2 Exception 13(b), and for all other purposes, including section 259B and 260C of the Corporations Act, Shareholders approve the renewal of the Company’s Employee Share Option Plan FOR FOR FOR FOR Page 4 of 46 (ESOP) and the issue of up to 76,120,634 securities under the ESOP in accordance with the terms set out in the Explanatory Notes.” A voting prohibition statement and voting exclusion statement applies to this Resolution. Please see below. The Chair intends to vote all undirected proxies FOR Resolution 6. Resolution 7: Approval of potential termination benefits under the ESOP To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: "That, for a period commencing from the date this Resolution is passed and ending upon the expiry of all Options issued or to be issued under the ESOP, approval be given for all purposes including Listing Rule 10.19, Part 2D.2 of the Corporations Act for the giving of benefits to any current or future person holding a managerial or executive office of the Company or a related body corporate in connection with that person ceasing to hold such office, on the terms set out in the Explanatory Notes.” A voting prohibition statement and voting exclusion statement applies to this Resolution. Please see below. Resolution 8: Approval of 10% Placement Facility To consider and, if thought fit, to pass with or without amendment the following resolution as a special resolution: “That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the issued capital of the Company (at the time of issue), calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions described in the Explanatory Notes, be and is hereby approved.” A voting exclusion statement applies to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 8. Resolution 9(a)-(b): Ratification of prior issue of Tranche 1 Placement Shares To consider, and if thought fit, pass with or without amendment each of the following resolutions as a separate ordinary resolution: "That, for the purposes of Listing Rule 7.4 and all other purposes, Shareholders ratify the prior issue of 300,000,000 Tranche 1 Placement Shares, as follows: (a) 150,862,330 Tranche 1 Placement Shares issued under Listing Rule 7.1; and (b) 149,137,670 Tranche 1 Placement Shares issued under Listing Rule 7.1A, on the terms and conditions and in the manner detailed in the Explanatory Notes.” A voting exclusion statement applies to these Resolutions. Please see below. The Board recommends you vote FORthese resolutions. The Chair intends to vote all undirected proxies FOR Resolution 9(a)-(b) (inclusive). FOR FOR Page 5 of 46 Resolution 10: Approval for issue of Tranche 2 Placement Shares To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of up to 138,000,000 Tranche 2 Placement Shares, on the terms and conditions set out in the Explanatory Notes." A voting exclusion statement applies to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 10. Resolution 11: Approval for issue of Placement Options To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of up to 219,000,000 Placement Options, on the terms and conditions set out in the Explanatory Notes." A voting exclusion statement applies to this Resolution. Please see below. The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 11. Resolution 12(a) – (b): Approval for issue of Related Party Placement Securities To consider, and if thought fit, pass with or without amendment each of the following resolutions as a separate ordinary resolution: “That, for the purposes of Listing Rule 10.11 and for all other purposes, Shareholders approve the issue of up to 33,000,000 Related Party Placement Securities, as follows: (a) up to 30,000,000 Related Party Placement Securities to Dr Michael Baker (or his nominee/s); and (b) up to 3,000,000 Related Party Placement Securities to Mr James Baker (or his nominee/s), on the terms and conditions set out in the Explanatory Notes." A voting exclusion statement applies to these Resolutions. Please see below. The Board recommends you vote FORthese resolutions. The Chair intends to vote all undirected proxies FOR Resolution 12(a)-(b) (inclusive). Resolution 13: Approval of issue of Broker Options to Blue Ocean and Cygnet Capital To consider, and if thought fit, pass with or without amendment the following resolution as an ordinary resolution: "That, for the purposes of Listing Rule 7.1 and all other purposes, Shareholders approve the issue of up to 50,000,000 Broker Options to Blue Ocean and Cygnet Capital (or their respective nominee/s), on the terms and conditions and in the manner detailed in the Explanatory Notes.” A voting exclusion statement applies to this Resolution. Please see below. FOR FOR FOR Page 6 of 46 The Board recommends you vote FORthis resolution. The Chair intends to vote all undirected proxies FOR Resolution 13. Further details in respect of all Resolutions are set out in the Explanatory Notes accompanying this Notice of Meeting. By the order of the Board Deborah Ambrosini Company Secretary Dated: 2nd September 2026 The accompanying Explanatory Notes and proxy form including Voting Instructions form part of this Notice of Meeting. FOR Page 7 of 46 VOTING PROHIBITION STATEMENTS Resolution 1: Adoption of the Remuneration Report for 2026 In accordance with sections 250BD and 250R of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of either of the following persons: (a) a member of the Key Management Personnel (KMP), details of whose remuneration are included in the Remuneration Report; or (b) a Closely Related Party of such a member. However, a person (the voter) described above may cast a vote on this Resolution as a proxy if the vote is not cast on behalf of a person described above and either: (a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the voter is the Chair and the appointment of the Chair as proxy: (i) does not specify the way the proxy is to vote on this Resolution; and (ii) expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the KMP. Resolution 3: Approval for issue of Restricted Stock Units to Dr Michael Baker In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either a member of the Key Management Personnel or a Closely Related Party of such member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Resolution 6: Renewal of Percheron Therapeutics Employee Share Option Plan and Resolution 7: Approval of potential termination benefits under the Percheron Therapeutic Employee Share Option Plan In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on the relevant Resolution if: (a) the proxy is either a member of the KMP or a Closely Related Party of such member; and (b) the appointment does not specify the way the proxy is to vote on the Resolution. However, the above prohibition does not apply if: (a) the proxy is the Chair; and the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the appointment expressly authorises the Chair to exercise the proxy even though the Resolution is connected directly or indirectly with remuneration of a member of the KMP. Further, in accordance with section 200E(2A) of the Corporations Act, a vote on Resolution 7 must not be cast by any participants or potential participants in the Employee Share Option Plan and their associates, otherwise the benefit of this Resolution will be lost by such a person in relation to that person's future Page 8 of 46 retirement. However, a vote may be cast by such a person if: (a) the person is appointed as proxy by writing that specifies the way the proxy is to vote on this Resolution; and (b) it is not cast on behalf of the person or an associate of the person. VOTING EXCLUSION STATEMENTS In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons: Resolution 3: Approval for issue of Restricted Stock Units to Dr Michael Baker The Company will disregard any votes cast in favour of Resolution 3 by or on behalf of Dr Michael Baker, and any person or any of their associates, who will obtain a material benefit as a result of the issue of Restricted Stock Units (except a benefit solely by reason of being a holder of Shares in the Company). Resolution 4: Ratification of prior issue of Adviser Options to Blue Ocean The Company will disregard any votes cast in favour of Resolution 4 by or on behalf of Blue Ocean, and any other person who participated in the issue of the Adviser Options, or any of their respective associates, or their nominees. Resolutions 5: Ratification of prior issue of Joint Lead Manager Options to Blue Ocean and Cygnet Capital The Company will disregard any votes cast in favour of Resolution 5 by or on behalf of Blue Ocean and Cygnet Capital, and any other person who participated in the issue of the Joint Lead Manager Options, or any of their respective associates, or their nominees. Resolution 6: Renewal of Percheron Therapeutics Employee Share Option Plan The Company will disregard any votes cast in favour of Resolution 6 by or on behalf of a person who is eligible to participate in the employee incentive scheme, or any of their respective associates. Resolution 7: Approval of potential termination benefits under the ESOP The Company will disregard any votes cast in favour of Resolution 7 by or on behalf of an officer of the Company or any of its child entities who is entitled to participate in a termination benefit. Special Resolution 8: Approval of 10% Placement Facility The Company will disregard any votes cast in favour of the Resolution by a person who is expected to participate in the 10% Placement Facility and a person who will obtain a material benefit as a result of the proposed issue, except a benefit solely by reason of being a holder of Shares in the Company, if this Resolution is passed, and any associates of those persons. As at the date of this Notice of Meeting the Company has no specific plans to issue equity securities under the 10% Placement Facility and therefore it is not known who (if any) may participate in a potential (if any) issue of equity securities under the 10% Placement Facility. Resolution 9(a): Ratification of prior issue of Tranche 1 Placement Shares The Company will disregard any votes cast in favour of Resolution 9(a) by or on behalf of a person who participated in the issue of those Tranche 1 Placement Shares, or any of the irrespective associates, or their nominees. Page 9 of 46 However, the above voting exclusion statements do not apply to a vote cast in favour of the Resolution by: (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Resolution 9(b): Ratification of prior issue of Tranche 1 Placement Shares The Company will disregard any votes cast in favour of Resolution 9(b) by or on behalf of a person who participated in the issue of those Tranche 1 Placement Shares, or any of the irrespective associates, or their nominees. Resolution 10: Approval for issue of Tranche 2 Placement Shares The Company will disregard any votes cast in favour of Resolution 10 by or on behalf of any person who will obtain a material benefit as a result of the proposed issue of the Tranche 2 Placement Shares (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their respective associates. Resolution 11: Approval for issue of Placement Options The Company will disregard any votes cast in favour of Resolution 11 by or on behalf of any person who will obtain a material benefit as a result of the proposed issue of the Placement Options (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their respective associates. Resolution 12(a): Approval for issue of Related Party Placement Securities The Company will disregard any votes cast in favour of Resolution 12(a) by or on behalf of Dr Michael Baker and any other person who will obtain a material benefit as a result of the proposed issue of these Related Party Placement Securities (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their respective associates. Resolution 12(b): Approval for issue of Related Party Placement Securities The Company will disregard any votes cast in favour of Resolution 12(b) by or on behalf of Mr James Baker and any other person who will obtain a material benefit as a result of the proposed issue of these Related Party Placement Securities (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their respective associates. Resolutions 13: Approval of issue of Broker Options to Blue Ocean and Cygnet Capital The Company will disregard any votes cast in favour of Resolution 13 by or on behalf of Blue Ocean and Cygnet Capital, and any other person who will obtain a material benefit as a result of the proposed issue of the Broker Options (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their respective associates. Page 10 of 46 NOTES Voting Entitlements In accordance with section 1074E(2)(g)(i) of the Corporations Act and regulation 7.11.37 of the Corporations Regulations 2001 (Cth), the Board has determined that a Shareholder’s voting entitlement at this Meeting will be taken to be the entitlement of the person shown in the register of members as at 7:00 pm (AEDT) on Monday, 5 October 2026. Transactions registered after that time will be disregarded in determining the Shareholder’s entitlement to attend and vote at the Meeting. Voting in person To vote in person, attend the Meeting on the date and at the place set out above. Attending the meeting virtually The Meeting will be virtually accessible to all Shareholders and will allow Shareholders, as a whole, a reasonable opportunity to participate without being physically present at the Meeting. The Company will announce details of how to register for and remotely attend the Meeting via the ASX Market Announcements Platform and on the Company’s website at www.percherontx.com.au. The technology used to hold the Meeting will be reasonable and Shareholders entitled to attend and vote at the Meeting will be able to: • view the Meeting live; • exercise a right to speak (including a right to ask questions) orally at the Meeting; and • cast votes in real time on a poll during the Meeting. Proxies • A Shareholder entitled to attend and vote at this Meeting is entitled to appoint a proxy (who need not be a Shareholder) to attend and vote in the Shareholder’s place. A proxy form accompanies this Notice of Meeting for this purpose. • A proxy form must be signed by a Shareholder or his or her attorney and, in the case of a joint holding, by each of the joint holders. • Shareholders who are entitled to cast two or more votes may appoint not more than two proxies to attend and vote at this Meeting. Shareholders wishing to appoint a second proxy should request an additional proxy form from the Company’s share registry – Boardroom Pty Limited. Where two proxies are appointed, both forms should be completed with the nominated proportion or number of votes each proxy may exercise. If no such proportion or number is specified, each proxy may exercise half of the votes. Fractions of votes are to be disregarded. • Where a Shareholder appoints two proxies, on a show of hands, neither proxy may vote if more than one proxy attends and, on a poll, each proxy may only exercise votes in respect of those shares or voting rights the proxy represents. • The appointment of one or more duly appointed proxies will not preclude a Shareholder from attending this Meeting and voting personally. If the Shareholder votes on a resolution, the proxy must not vote as the Shareholder’s proxy on that resolution. • Any instrument appointing a proxy in which the name of the appointee is not completed, is regarded as given in favour of the chair of the Meeting in accordance with section 250BC of the Corporations Act. • In the case of joint holders of shares, if more than one holder votes at any Meeting, only the vote of the first named of the joint holders in the share register of the Company will be counted. • To be effective, proxy forms (and the power of attorney or other authority (if any) under which it is signed (or an attested copy)) must be received by the Company at its registered office or delivered in person, by mail or by fax to the Company Secretary’s office (details below). Completed proxy forms must be received no later than 48 hours before the appointed time of the Meeting. Page 11 of 46 • Proxy forms may be lodged: By Mail: Boardroom Pty Limited GPO Box 3993 SYDNEY NSW 2001 In person: Boardroom Pty Limited Level 8, 210 George Street SYDNEY NSW 2000 Online voting: https://www.votingonline.com.au/peragm2026 Proxies must be received at least 48 hours before the Meeting (being, by no later than 10.00 am (AEDT) on Monday, 5 October 2026). • Proxies given by a corporation must be signed either under seal or under the hand of a duly authorised attorney. In addition, should the constitution of a corporation permit the execution of documents without using a common seal, the documents must be signed by two directors or a director and a company secretary, or for a proprietary company that has a sole director who is also a company secretary, that director. • If a body corporate is appointed as proxy, please write the full name of that body corporate (e.g. Company X Pty Ltd). Do not use abbreviations. The body corporate will need to ensure that it: o Appoints an individual as its corporate representative to exercise its powers at meetings, in accordance with section 250D of the Corporations Act; and o Provides satisfactory evidence of the appointment of its corporate representative prior to commencement of the Meeting. If no such evidence is received before the meeting, then the body corporate (through its representative) will not be permitted to act as your proxy. Body corporate representatives • A corporation, by resolution of its directors, may authorise a person to act as its representative to vote at the Meeting. • A representative appointed by a corporation may be entitled to execute the same powers on behalf of the corporation as the corporation could exercise if it were an individual shareholder of the Company. • To evidence the authorisation, either a certificate of corporate body representative executed by the corporation or under the hand of its attorney or an equivalent document evidencing the appointment will be required. • The certificate or equivalent document must be produced prior to the Meeting. Appointing the chair as your proxy The proxy form accompanying this Notice of Meeting contains detailed instructions regarding how to complete the proxy form if a shareholder wishes to appoint the chair of the Meeting as his or her proxy. You should read those instructions carefully. Subject to the ASX Listing Rules and the Corporations Act the chair of the Meeting intends to exercise all available proxies by voting in favour of Resolutions 1-13 (inclusive), unless the Shareholder has expressly indicated a different voting intention. Submitting questions Shareholders may submit questions in advance of the Meeting to the Company. Questions must be submitted by emailing the Company Secretary at deborah.ambrosini@percherontx.com by 5:00pm (AEST) on Wednesday, 30 September 2026. Shareholders will also have the opportunity to submit questions during the Meeting in respect to the formal items of business. In order to ask a question during the Meeting, please follow the instructions from the Chair. Page 12 of 46 The Chair will attempt to respond to the questions during the Meeting. The Chair will request prior to a Shareholder asking a question that they identify themselves (including the entity name of their shareholding and the number of shares they hold). Definitions Words that are defined in the Glossary have the same meaning when used in this Notice of Meeting unless the context requires, or the definitions in the Glossary provide, otherwise. Page 13 of 46 PERCHERON THERAPEUTICS LIMITED ACN 095 060 745 EXPLANATORY NOTES TO NOTICE OF 2026 ANNUAL GENERAL MEETING These Explanatory Notes accompany and form part of the Percheron Therapeutics Limited Notice of Annual General Meeting (Meeting) to be held both in person and virtually at 10.00 am (AEDT) on Wednesday, 7 October 2026. The Notice of Meeting should be read together with these Explanatory Notes. BUSINESS OF THE MEETING Resolution 1: Non-binding resolution to adopt 2026 Remuneration Report 1.1 Background Pursuant to the Corporations Act, at the annual general meeting of a listed company, the Company must propose a resolution that the remuneration report be adopted. The purpose of Resolution 1 is to lay before the Shareholders, the Company’s Remuneration Report for the year ended 30 June 2026 (Remuneration Report) so that Shareholders may ask questions about or make comments on the management of the Company in accordance with the requirements of the Corporations Act and vote on an advisory and non-binding resolution to adopt the Remuneration Report. The Board will consider the outcome of the vote made by Shareholders on the Remuneration Report at the Meeting when reviewing the Company’s remuneration policies. The Remuneration Report is contained within the 2026 Annual Report. You may view the 2026 Annual Report by visiting the Company’s website www.percherontx.com.au, or you may order a hard copy of the 2026 Annual Report by phoning +61 (0)3 9827 8999. The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about or make comments on the Remuneration Report. 1.2 Voting Consequences The vote on the Resolution for adoption of the Remuner